TDMS Study 89029-06 Pathology Tables
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
MERGED GROUPS
Facility: I. I. T. Research Institute
Chemical CAS #: ELECTROMAG
Lock Date: 09/09/97
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Merge 001 001,011 SHAM CONTROL
Merge 002 002,012 SHAM CONTROL
Merge 003 003,013 .02 GAUSS
Merge 004 004,014 .02 GAUSS
Merge 005 005,015 2 GAUSS
Merge 006 006,016 2 GAUSS
Merge 007 009,019 10 GAUSS
Merge 008 010,020 10 GAUSS
Merge 009 007,017 10 GAUSS INTER
Merge 010 008,018 10 GAUSS INTER
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 100 100 100 100 100
Early Deaths
Natural Death 23 18 13 18 15
Moribund Sacrifice 6 7 6 7 8
Accidently Killed 1 1 2 1
Survivors
Natural Death 1
Terminal Sacrifice 69 74 79 74 77
Animals Examined Microscopically 100 100 100 100 100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (97) (100) (99) (98) (100)
Gallbladder (70) (84) (87) (79) (91)
Histiocytic Sarcoma 1 (1%) 2 (2%)
Rhabdomyosarcoma, Metastatic, Intestine
Small, Jejunum 1 (1%)
Intestine Large, Colon (82) (88) (90) (90) (93)
Histiocytic Sarcoma 1 (1%)
Intestine Large, Cecum (78) (87) (90) (87) (92)
Histiocytic Sarcoma 1 (1%)
Leiomyosarcoma 1 (1%)
Serosa, Histiocytic Sarcoma 1 (1%)
Intestine Small, Duodenum (77) (85) (90) (87) (91)
Histiocytic Sarcoma 1 (1%)
Leiomyosarcoma 1 (1%)
Polyp Adenomatous 1 (1%) 1 (1%)
Intestine Small, Jejunum (79) (86) (89) (91) (92)
Histiocytic Sarcoma 1 (1%)
Sarcoma, Metastatic, Skin 1 (1%)
Serosa, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (1%)
Intestine Small, Ileum (78) (85) (90) (87) (93)
Histiocytic Sarcoma 1 (1%) 1 (1%)
Liver (98) (97) (98) (99) (100)
Hemangiosarcoma 1 (1%) 1 (1%) 1 (1%)
Hemangiosarcoma, Metastatic, Spleen 1 (1%)
Hepatocellular Carcinoma 6 (6%) 5 (5%) 6 (6%) 6 (6%) 6 (6%)
Hepatocellular Carcinoma, Multiple 1 (1%)
Hepatocellular Adenoma 15 (15%) 8 (8%) 19 (19%) 17 (17%) 11 (11%)
Hepatocellular Adenoma, Multiple 2 (2%) 2 (2%) 1 (1%) 1 (1%) 2 (2%)
Hepatocholangiocarcinoma 1 (1%)
Histiocytic Sarcoma 2 (2%) 2 (2%) 6 (6%)
Page 2
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (1%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 2 (2%) 1 (1%) 1 (1%)
Mesentery (36) (27) (30) (30) (53)
Histiocytic Sarcoma 4 (8%)
Leiomyosarcoma, Metastatic, Intestine Small,
Duodenum 1 (3%)
Liposarcoma 3 (11%) 1 (3%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 2 (6%)
Sarcoma 1 (3%) 2 (7%) 1 (2%)
Pancreas (87) (94) (96) (94) (95)
Histiocytic Sarcoma 3 (3%)
Rhabdomyosarcoma, Metastatic, Uncertain
Primary Site 1 (1%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) 1 (1%)
Sarcoma, Metastatic, Mesentery 1 (1%)
Sarcoma, Metastatic, Skin 1 (1%)
Salivary Glands (94) (98) (97) (98) (99)
Carcinoma 1 (1%)
Histiocytic Sarcoma 1 (1%) 2 (2%)
Stomach, Forestomach (91) (92) (93) (94) (97)
Basal Cell Adenoma 1 (1%)
Sarcoma 1 (1%)
Squamous Cell Carcinoma 1 (1%)
Squamous Cell Papilloma 1 (1%) 1 (1%) 1 (1%)
Stomach, Glandular (86) (90) (93) (93) (94)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (1%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (98) (100) (94) (99) (96)
Heart (98) (100) (100) (99) (100)
Hemangiosarcoma 1 (1%)
Histiocytic Sarcoma 2 (2%)
Osteosarcoma, Metastatic, Bone 1 (1%)
Sarcoma, Metastatic, Skin 1 (1%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (92) (98) (99) (99) (99)
Histiocytic Sarcoma 2 (2%)
Capsule, Adenoma 2 (2%)
Capsule, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (1%)
Capsule, Sarcoma 1 (1%)
Adrenal Medulla (90) (95) (97) (97) (98)
Pheochromocytoma Benign 3 (3%) 2 (2%) 2 (2%)
Bilateral, Histiocytic Sarcoma 1 (1%)
Bilateral, Pheochromocytoma Benign 1 (1%)
Islets, Pancreatic (87) (95) (94) (94) (94)
Adenoma 2 (2%) 7 (7%) 2 (2%) 3 (3%)
Histiocytic Sarcoma 2 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Parathyroid Gland (63) (53) (53) (53) (58)
Pineal Gland (52) (37) (67) (61) (61)
Histiocytic Sarcoma 2 (3%)
Pituitary Gland (83) (92) (87) (89) (93)
Histiocytic Sarcoma 1 (1%)
Pars Distalis, Adenoma 16 (19%) 17 (18%) 18 (21%) 21 (24%) 15 (16%)
Pars Distalis, Adenoma, Multiple 1 (1%) 2 (2%) 1 (1%)
Pars Distalis, Histiocytic Sarcoma 1 (1%)
Pars Intermedia, Adenoma 1 (1%) 1 (1%)
Thyroid Gland (92) (99) (98) (98) (98)
Adenoma 1 (1%) 1 (1%) 2 (2%) 1 (1%)
Adenoma, Multiple 1 (1%)
Histiocytic Sarcoma 1 (1%)
Bilateral, Adenoma 1 (1%)
C-Cell, Adenoma 1 (1%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Tissue NOS (1) (1) (3)
Leiomyosarcoma, Metastatic, Intestine Small,
Duodenum 1 (33%)
Rhabdomyosarcoma 1 (100%)
Sarcoma 1 (100%) 1 (33%)
Schwannoma Benign 1 (33%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (89) (84) (85) (84) (82)
Bilateral, Histiocytic Sarcoma 1 (1%)
Bilateral, Sarcoma 1 (1%)
Ovary (79) (91) (95) (94) (96)
Cystadenoma 3 (4%) 3 (3%) 2 (2%) 2 (2%)
Granulosa Cell Tumor Benign 2 (3%) 3 (3%) 1 (1%)
Hemangioma 1 (1%) 1 (1%) 2 (2%)
Hemangiosarcoma 1 (1%) 1 (1%)
Histiocytic Sarcoma 1 (1%)
Luteoma 1 (1%) 1 (1%)
Rhabdomyosarcoma, Metastatic, Intestine
Small, Jejunum 1 (1%)
Bilateral, Histiocytic Sarcoma 1 (1%)
Bilateral, Luteoma 1 (1%) 1 (1%)
Uterus (92) (97) (98) (99) (100)
Hemangioma 1 (1%)
Hemangiosarcoma 1 (1%) 1 (1%)
Lymphangioma 1 (1%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Bilateral, Histiocytic Sarcoma 1 (1%)
Cervix, Histiocytic Sarcoma 1 (1%)
Endometrium, Polyp Stromal 1 (1%) 1 (1%) 1 (1%)
Vagina (1) (1)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (96) (99) (97) (99) (100)
Histiocytic Sarcoma 1 (1%) 1 (1%)
Sarcoma 1 (1%)
Lymph Node (19) (15) (4) (14) (12)
Histiocytic Sarcoma 1 (8%)
Sarcoma, Metastatic, Skin 1 (5%) 1 (7%)
Schwannoma Malignant, Metastatic, Skin 1 (5%)
Bronchial, Histiocytic Sarcoma 1 (5%)
Iliac, Sarcoma, Metastatic, Skin 1 (7%)
Inguinal, Histiocytic Sarcoma 1 (5%) 1 (8%)
Lumbar, Histiocytic Sarcoma 2 (13%) 2 (17%)
Mediastinal, Histiocytic Sarcoma 2 (11%) 1 (7%) 1 (8%)
Renal, Histiocytic Sarcoma 1 (5%) 2 (13%)
Lymph Node, Mandibular (84) (94) (89) (91) (92)
Histiocytic Sarcoma 2 (2%) 1 (1%) 2 (2%)
Lymph Node, Mesenteric (83) (88) (89) (92) (95)
Histiocytic Sarcoma 2 (2%) 2 (2%) 4 (4%)
Plasma Cell Tumor Malignant 1 (1%)
Page 5
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Rhabdomyosarcoma, Metastatic, Tissue NOS 1 (1%)
Rhabdomyosarcoma, Metastatic, Uncertain
Primary Site 1 (1%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Spleen (91) (93) (95) (93) (99)
Hemangiosarcoma 1 (1%)
Histiocytic Sarcoma 2 (2%) 2 (2%) 2 (2%) 4 (4%)
Plasma Cell Tumor Malignant 1 (1%) 1 (1%) 1 (1%)
Thymus (78) (92) (84) (75) (89)
Histiocytic Sarcoma 1 (1%) 2 (2%) 3 (3%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Sarcoma, Metastatic, Skin 1 (1%)
Thymoma Benign 1 (1%) 1 (1%)
Thymoma Malignant 1 (1%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (94) (98) (99) (99) (98)
Adenoma 1 (1%) 2 (2%) 1 (1%)
Carcinoma 1 (1%) 1 (1%)
Histiocytic Sarcoma 1 (1%)
Skin (99) (100) (100) (100) (100)
Basal Cell Carcinoma 1 (1%)
Fibrosarcoma 1 (1%)
Hemangioma 1 (1%) 1 (1%)
Hemangiosarcoma 1 (1%) 1 (1%) 2 (2%)
Rhabdomyosarcoma, Metastatic, Uncertain
Primary Site 1 (1%)
Sarcoma 4 (4%) 5 (5%) 2 (2%) 3 (3%) 4 (4%)
Schwannoma Malignant 2 (2%) 1 (1%) 4 (4%) 1 (1%) 2 (2%)
Trichoepithelioma 1 (1%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (100) (100) (99) (99) (99)
Femur, Hemangiosarcoma, Metastatic, Spleen 1 (1%)
Femur, Osteosarcoma 1 (1%)
Sternum, Sarcoma, Metastatic, Mesentery 1 (1%)
Vertebra, Osteosarcoma 1 (1%)
Skeletal Muscle (7) (3) (3) (4) (4)
Hemangiosarcoma, Metastatic, Heart 1 (25%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (25%)
Rhabdomyosarcoma 3 (43%) 1 (33%) 1 (25%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (99) (100) (98) (98) (100)
Ventricle, Hamartoma, LIPOMATOUS 1 (1%) 2 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (95) (100) (99) (99) (100)
Alveolar/Bronchiolar Adenoma 9 (9%) 6 (6%) 5 (5%) 6 (6%)
Alveolar/Bronchiolar Carcinoma 2 (2%) 6 (6%) 2 (2%) 1 (1%) 1 (1%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (1%)
Basal Cell Carcinoma, Metastatic, Skin 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (2%) 1 (1%)
Histiocytic Sarcoma 1 (1%) 2 (2%) 2 (2%) 3 (3%)
Osteosarcoma, Metastatic, Bone 1 (1%) 1 (1%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (1%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Sarcoma, Metastatic, Mesentery 1 (1%)
Sarcoma, Metastatic, Skin 1 (1%) 1 (1%) 1 (1%) 1 (1%) 2 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (1%)
Mediastinum, Histiocytic Sarcoma 1 (1%)
Mediastinum, Osteosarcoma, Metastatic, Bone 1 (1%)
Mediastinum, Schwannoma Malignant,
Metastatic, Skin 1 (1%)
Serosa, Sarcoma, Metastatic, Mesentery 1 (1%)
Nose (99) (100) (99) (100) (99)
Trachea (94) (100) (98) (99) (98)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (98) (97) (99) (96) (97)
Adenoma 9 (9%) 7 (7%) 14 (14%) 12 (13%) 12 (12%)
Carcinoma 2 (2%)
Histiocytic Sarcoma 1 (1%)
Bilateral, Adenoma 1 (1%) 1 (1%) 1 (1%)
Lacrimal Gland (1)
Bilateral, Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (92) (96) (98) (98) (99)
Histiocytic Sarcoma 1 (1%) 1 (1%)
Osteosarcoma, Metastatic, Bone 1 (1%)
Plasma Cell Tumor Malignant, Metastatic,
Uncertain Primary Site 1 (1%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Bilateral, Histiocytic Sarcoma 1 (1%) 3 (3%)
Urinary Bladder (79) (87) (94) (89) (92)
Carcinoma 1 (1%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(100) *(100) *(100) *(100) *(100)
Histiocytic Sarcoma 2 (2%) 2 (2%) 2 (2%) 6 (6%)
Lymphoma Malignant 32 (32%) 31 (31%) 22 (22%) 26 (26%) 20 (20%)
Mesothelioma Malignant 1 (1%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 8
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 78 80 72 71 68
Total Primary Neoplasms 132 122 124 117 110
Total Animals with Benign Neoplasms 52 49 54 49 44
Total Benign Neoplasms 68 58 77 71 61
Total Animals with Malignant Neoplasms 55 58 38 38 44
Total Malignant Neoplasms 64 64 47 46 49
Total Animals with Metastatic Neoplasms 9 8 5 5 6
Total Metastatic Neoplasm 14 21 8 8 12
Total Animals with Malignant Neoplasms 2 2 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 9
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 100 100 100 100 100
Early Deaths
Natural Death 13 15 10 24 18
Moribund Sacrifice 11 13 6 14 8
Survivors
Terminal Sacrifice 76 72 84 62 73
Natural Death 1
Animals Examined Microscopically 100 100 100 100 100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (97) (97) (98) (96) (99)
Periesophageal Tissue, Sarcoma, Metastatic,
Uncertain Primary Site 1 (1%)
Gallbladder (84) (83) (84) (75) (82)
Adenoma 1 (1%)
Carcinoma, Metastatic, Intestine Small,
Duodenum 1 (1%)
Intestine Large, Colon (93) (94) (92) (83) (85)
Intestine Large, Rectum (93) (90) (93) (81) (87)
Intestine Large, Cecum (90) (89) (92) (81) (85)
Intestine Small, Duodenum (89) (88) (92) (79) (84)
Carcinoma 2 (2%) 1 (1%) 1 (1%)
Polyp Adenomatous 2 (2%) 1 (1%)
Intestine Small, Jejunum (89) (94) (93) (80) (85)
Carcinoma 1 (1%) 1 (1%) 3 (3%) 1 (1%)
Intestine Small, Ileum (91) (89) (92) (81) (84)
Carcinoma 1 (1%)
Liver (100) (100) (100) (98) (99)
Carcinoma, Metastatic, Islets, Pancreatic 1 (1%)
Carcinoma, Metastatic, Pancreas 1 (1%)
Carcinoma, Metastatic, Intestine Small,
Duodenum 1 (1%)
Hemangiosarcoma 4 (4%) 2 (2%) 3 (3%) 5 (5%) 4 (4%)
Hemangiosarcoma, Metastatic, Skin 1 (1%)
Hemangiosarcoma, Metastatic, Spleen 1 (1%) 1 (1%)
Hepatoblastoma 2 (2%) 2 (2%) 1 (1%) 4 (4%) 5 (5%)
Hepatocellular Carcinoma 19 (19%) 14 (14%) 20 (20%) 15 (15%) 23 (23%)
Hepatocellular Adenoma 28 (28%) 26 (26%) 32 (32%) 21 (21%) 30 (30%)
Hepatocellular Adenoma, Multiple 2 (2%) 2 (2%)
Hepatocholangiocarcinoma 1 (1%)
Histiocytic Sarcoma 1 (1%) 1 (1%) 1 (1%) 1 (1%)
Rhabdomyosarcoma, Metastatic, Heart 1 (1%)
Page 10
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Mesentery (13) (16) (8) (10) (9)
Carcinoma, Metastatic, Islets, Pancreatic 1 (13%)
Carcinoma, Metastatic, Intestine Small,
Duodenum 1 (6%)
Hemangiosarcoma 1 (6%) 1 (13%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (11%)
Rhabdomyosarcoma, Metastatic, Heart 1 (13%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (10%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (10%)
Oral Mucosa (2)
Squamous Cell Carcinoma 1 (50%)
Pancreas (99) (99) (98) (95) (98)
Carcinoma 1 (1%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (1%)
Carcinoma, Metastatic, Intestine Small,
Duodenum 1 (1%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
Sarcoma 1 (1%)
Schwannoma Malignant, Metastatic, Skin 1 (1%)
Salivary Glands (99) (99) (98) (96) (99)
Stomach, Forestomach (99) (98) (97) (96) (99)
Sarcoma 1 (1%)
Squamous Cell Carcinoma 1 (1%)
Squamous Cell Papilloma 1 (1%)
Stomach, Glandular (94) (93) (97) (87) (93)
Serosa, Hemangiosarcoma, Metastatic,
Mesentery 1 (1%)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (97) (94) (100) (96) (98)
Aorta, Adventitia, Rhabdomyosarcoma,
Metastatic, Heart 1 (1%)
Aorta, Adventitia, Sarcoma, Metastatic,
Uncertain Primary Site 1 (1%)
Heart (100) (100) (100) (99) (100)
Carcinoma, Metastatic, Kidney 1 (1%)
Hemangiosarcoma 2 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (1%) 2 (2%) 2 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (1%) 1 (1%) 1 (1%)
Rhabdomyosarcoma 1 (1%) 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (99) (96) (99) (94) (97)
Adenoma 3 (3%) 1 (1%) 5 (5%)
Bilateral, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (1%)
Capsule, Carcinoma, Metastatic, Intestine
Small, Duodenum 1 (1%)
Adrenal Medulla (98) (93) (99) (91) (96)
Pheochromocytoma Malignant 2 (2%)
Pheochromocytoma Benign 1 (1%) 1 (1%)
Bilateral, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (1%)
Islets, Pancreatic (99) (99) (98) (97) (98)
Adenoma 1 (1%) 3 (3%) 1 (1%) 1 (1%)
Carcinoma 2 (2%) 1 (1%) 1 (1%)
Hemangiosarcoma, Metastatic, Mesentery 1 (1%)
Pineal Gland (55) (58) (62) (45) (57)
Pituitary Gland (83) (84) (82) (84) (86)
Pars Distalis, Adenoma 1 (1%) 1 (1%)
Pars Intermedia, Adenoma 1 (1%)
Thyroid Gland (99) (98) (98) (97) (98)
Adenoma 1 (1%) 1 (1%) 1 (1%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2) (4) (1) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Histiocytic Sarcoma 1 (25%)
Schwannoma Malignant 1 (100%)
Pelvic, Sarcoma 1 (25%)
Thoracic, Fat, Hemangioma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (98) (99) (99) (96) (98)
Carcinoma, Metastatic, Islets, Pancreatic 1 (1%)
Hemangiosarcoma, Metastatic, Skin 1 (1%)
Histiocytic Sarcoma 1 (1%)
Bilateral, Carcinoma, Metastatic, Intestine
Small, Duodenum 1 (1%)
Bilateral, Sarcoma, Metastatic, Pancreas 1 (1%)
Preputial Gland (98) (98) (100) (95) (99)
Prostate (98) (92) (94) (94) (92)
Adenoma 1 (1%)
Page 12
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Histiocytic Sarcoma 1 (1%)
Sarcoma, Metastatic, Pancreas 1 (1%)
Seminal Vesicle (99) (97) (98) (98) (98)
Carcinoma 1 (1%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (1%)
Hemangiosarcoma, Metastatic, Mesentery 1 (1%)
Bilateral, Sarcoma, Metastatic, Pancreas 1 (1%)
Testes (99) (98) (100) (96) (98)
Adenoma 1 (1%) 1 (1%) 2 (2%) 1 (1%) 1 (1%)
Hemangiosarcoma 1 (1%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (99) (99) (99) (99) (100)
Hemangiosarcoma, Metastatic, Liver 2 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (1%)
Hemangiosarcoma, Metastatic, Spleen 1 (1%) 1 (1%) 1 (1%)
Mast Cell Tumor Benign 1 (1%)
Lymph Node (6) (6) (5) (3) (7)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (14%)
Hemangiosarcoma 1 (14%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (14%)
Histiocytic Sarcoma 1 (17%)
Plasma Cell Tumor Malignant 1 (17%)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (20%)
Lumbar, Hemangiosarcoma, Metastatic,
Mesentery 1 (17%)
Lumbar, Histiocytic Sarcoma 1 (33%)
Lymph Node, Mandibular (92) (92) (92) (89) (90)
Histiocytic Sarcoma 1 (1%)
Lymph Node, Mesenteric (87) (90) (96) (85) (92)
Carcinoma, Metastatic, Islets, Pancreatic 1 (1%)
Carcinoma, Metastatic, Intestine Small,
Duodenum 1 (1%)
Histiocytic Sarcoma 1 (1%) 1 (1%)
Plasma Cell Tumor Malignant 1 (1%)
Rhabdomyosarcoma, Metastatic, Heart 1 (1%) 1 (1%)
Sarcoma, Metastatic, Pancreas 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Spleen (99) (98) (98) (93) (98)
Hemangiosarcoma 2 (2%) 5 (5%) 3 (3%) 1 (1%)
Hemangiosarcoma, Metastatic, Skin 1 (1%)
Histiocytic Sarcoma 1 (1%) 1 (1%)
Thymus (69) (68) (63) (68) (60)
Page 13
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (99) (99) (100) (100) (100)
Carcinoma, Metastatic, Harderian Gland 1 (1%)
Hemangiosarcoma 1 (1%)
Histiocytic Sarcoma 1 (1%)
Rhabdomyosarcoma, Metastatic, Heart 1 (1%)
Sarcoma 1 (1%)
Schwannoma Benign 1 (1%)
Schwannoma Malignant 1 (1%) 1 (1%)
Squamous Cell Papilloma 1 (1%) 1 (1%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (97) (100) (99) (99) (99)
Femur, Hemangiosarcoma, Metastatic, Liver 1 (1%)
Femur, Hemangiosarcoma, Metastatic, Spleen 1 (1%)
Skeletal Muscle (8) (7) (2) (7) (4)
Hemangiosarcoma, Metastatic, Mesentery 1 (14%)
Rhabdomyosarcoma 1 (14%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (100) (99) (100) (99) (100)
Meninges, Sarcoma 1 (1%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (100) (99) (100) (99) (99)
Alveolar/Bronchiolar Adenoma 24 (24%) 11 (11%) 7 (7%) 14 (14%) 13 (13%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (2%) 2 (2%) 2 (2%) 3 (3%)
Alveolar/Bronchiolar Carcinoma 8 (8%) 11 (11%) 12 (12%) 10 (10%) 9 (9%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (1%)
Carcinoma, Metastatic, Harderian Gland 1 (1%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (1%)
Carcinoma, Metastatic, Kidney 1 (1%)
Carcinoma, Metastatic, Pancreas 1 (1%)
Hemangiosarcoma, Metastatic, Liver 1 (1%)
Hemangiosarcoma, Metastatic, Mesentery 1 (1%)
Hepatoblastoma, Metastatic, Liver 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (2%) 5 (5%) 8 (8%) 5 (5%) 9 (9%)
Page 14
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Histiocytic Sarcoma 1 (1%) 1 (1%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (1%)
Rhabdomyosarcoma, Metastatic, Heart 1 (1%) 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%) 1 (1%)
Schwannoma Malignant, Metastatic, Skin 1 (1%)
Arteriole, Hepatoblastoma, Metastatic, Liver 1 (1%)
Nose (99) (99) (100) (97) (100)
Sinus, Sarcoma, Metastatic, Eye 1 (1%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (2) (2) (1)
Retrobulbar, Sarcoma 1 (50%)
Harderian Gland (99) (99) (100) (96) (99)
Adenoma 12 (12%) 14 (14%) 16 (16%) 10 (10%) 11 (11%)
Carcinoma 1 (1%) 3 (3%)
Sarcoma, Metastatic, Eye 1 (1%)
Bilateral, Adenoma 2 (2%) 2 (2%)
Bilateral, Carcinoma 1 (1%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (99) (98) (99) (96) (97)
Sarcoma, Metastatic, Pancreas 1 (1%)
Bilateral, Carcinoma 1 (1%)
Bilateral, Rhabdomyosarcoma, Metastatic,
Heart 1 (1%)
Capsule, Rhabdomyosarcoma, Metastatic, Heart 1 (1%)
Cortex, Rhabdomyosarcoma, Metastatic, Heart 1 (1%)
Renal Tubule, Adenoma 1 (1%) 2 (2%)
Urinary Bladder (98) (95) (95) (93) (94)
Histiocytic Sarcoma 1 (1%)
Papilloma 1 (1%)
Sarcoma, Metastatic, Pancreas 1 (1%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(100) *(100) *(100) *(100) *(100)
Histiocytic Sarcoma 1 (1%) 1 (1%) 3 (3%) 1 (1%) 1 (1%)
Leukemia Granulocytic 1 (1%)
Lymphoma Malignant 8 (8%) 7 (7%) 4 (4%) 7 (7%) 6 (6%)
Mesothelioma Malignant 2 (2%) 1 (1%)
* Number of animals with any tissue examined microscopically
Page 15
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(100) *(100) *(100) *(100) *(100)
____________________________________________________________________________________________________________________________________
Page 16
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98
Route: MAGNETIC FIELDS Time: 12:40:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS
CONTROL GAUSS GAUSS INTER
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 71 81 72 74 76
Total Primary Neoplasms 127 123 122 112 124
Total Animals with Benign Neoplasms 54 50 54 47 52
Total Benign Neoplasms 77 64 68 57 65
Total Animals with Malignant Neoplasms 40 49 45 49 48
Total Malignant Neoplasms 50 59 54 55 59
Total Animals with Metastatic Neoplasms 8 11 15 17 13
Total Metastatic Neoplasm 9 23 28 36 22
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 17
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------